Whole blood transcript and protein abundance of the vascular endothelial growth factor family relate to cognitive performance
- PMID: 36680854
- PMCID: PMC9957941
- DOI: 10.1016/j.neurobiolaging.2023.01.002
Whole blood transcript and protein abundance of the vascular endothelial growth factor family relate to cognitive performance
Abstract
The vascular endothelial growth factor (VEGF) family of genes has been implicated in the clinical development of Alzheimer's Disease (AD). A previous study identified associations between gene expression of VEGF family members in the prefrontal cortex and cognitive performance and AD pathology. This study explored if those associations were also observed in the blood. Consistent with previous observations in brain tissue, higher blood gene expression of placental growth factor (PGF) was associated with a faster rate of memory decline (p=0.04). Higher protein abundance of FMS-related receptor tyrosine kinase 4 (FLT4) in blood was associated with biomarker levels indicative of lower amyloid and tau pathology, opposite the direction observed in brain. Also, higher gene expression of VEGFB in blood was associated with better baseline memory (p=0.008). Notably, we observed that higher gene expression of VEGFB in blood was associated with lower expression of VEGFB in the brain (r=-0.19, p=0.02). Together, these results suggest that the VEGFB, FLT4, and PGF alterations in the AD brain may be detectable in the blood compartment.
Keywords: Alzheimer's disease; Blood biomarkers; Mild Cognitive Impairment; VEGF.
Published by Elsevier Inc.
Conflict of interest statement
Conflicts of Interest
HZ has served at scientific advisory boards and/or as a consultant for Alector, Eisai, Denali, Roche Diagnostics, Wave, Samumed, Siemens Healthineers, Pinteon Therapeutics, Nervgen, AZTherapies, CogRx and Red Abbey Labs, has given lectures in symposia sponsored by Cellectricon, Fujirebio, Alzecure and Biogen, and is a co-founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program (outside submitted work). KB has served as a consultant, at advisory boards, or at data monitoring committees for Abcam, Axon, Biogen, JOMDD/Shimadzu. Julius Clinical, Lilly, MagQu, Novartis, Prothena, Roche Diagnostics, and Siemens Healthineers, and is a co-founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program (all outside the work presented in this paper). TH is a member of the scientific advisory board for Vivid Genomics (also outside the work presented herein).
Figures



Similar articles
-
Plasma VEGFA and PGF impact longitudinal tau and cognition in preclinical Alzheimer's disease.Brain. 2024 Jun 3;147(6):2158-2168. doi: 10.1093/brain/awae034. Brain. 2024. PMID: 38315899 Free PMC article.
-
Brain expression of the vascular endothelial growth factor gene family in cognitive aging and alzheimer's disease.Mol Psychiatry. 2021 Mar;26(3):888-896. doi: 10.1038/s41380-019-0458-5. Epub 2019 Jul 22. Mol Psychiatry. 2021. PMID: 31332262 Free PMC article.
-
The role of vascular endothelial growth factor in neurodegeneration and cognitive decline: exploring interactions with biomarkers of Alzheimer disease.JAMA Neurol. 2015 May;72(5):520-9. doi: 10.1001/jamaneurol.2014.4761. JAMA Neurol. 2015. PMID: 25751166 Free PMC article.
-
Multi-omic characterization of brain changes in the vascular endothelial growth factor family during aging and Alzheimer's disease.Neurobiol Aging. 2023 Jun;126:25-33. doi: 10.1016/j.neurobiolaging.2023.01.010. Epub 2023 Jan 26. Neurobiol Aging. 2023. PMID: 36905877 Free PMC article.
-
Understanding disease progression and improving Alzheimer's disease clinical trials: Recent highlights from the Alzheimer's Disease Neuroimaging Initiative.Alzheimers Dement. 2019 Jan;15(1):106-152. doi: 10.1016/j.jalz.2018.08.005. Epub 2018 Oct 13. Alzheimers Dement. 2019. PMID: 30321505 Review.
Cited by
-
Combination treatment with cilostazol and isosorbide mononitrate attenuates microemboli-mediated vascular cognitive impairment and improves imaging and plasma biomarkers in diabetic rats.Exp Neurol. 2025 Jan;383:115030. doi: 10.1016/j.expneurol.2024.115030. Epub 2024 Oct 25. Exp Neurol. 2025. PMID: 39490626
-
Association of Neurotrophic Factors at Midlife With In Vivo Measures of β-Amyloid and Tau Burden 15 Years Later in Dementia-Free Adults.Neurology. 2024 Apr 9;102(7):e209198. doi: 10.1212/WNL.0000000000209198. Epub 2024 Mar 12. Neurology. 2024. PMID: 38471064 Free PMC article.
-
LC-MS/MS proteomics identifies plasma proteins related to cognition over 9-year follow-up.Alzheimers Dement. 2025 Jun;21(6):e70276. doi: 10.1002/alz.70276. Alzheimers Dement. 2025. PMID: 40469059 Free PMC article.
-
Plasma VEGFA and PGF impact longitudinal tau and cognition in preclinical Alzheimer's disease.Brain. 2024 Jun 3;147(6):2158-2168. doi: 10.1093/brain/awae034. Brain. 2024. PMID: 38315899 Free PMC article.
-
Vascular endothelial growth factor receptor-1 (FLT1) interactions with amyloid-beta in Alzheimer's disease: A putative biomarker of amyloid-induced vascular damage.Neurobiol Aging. 2025 Mar;147:141-149. doi: 10.1016/j.neurobiolaging.2024.12.010. Epub 2024 Dec 25. Neurobiol Aging. 2025. PMID: 39752902 Free PMC article.
References
-
- Bennett RE, Robbins AB, Hu M, Cao X, Betensky RA, Clark T, Das S, & Hyman BT (2018). Tau induces blood vessel abnormalities and angiogenesis-related gene expression in P301L transgenic mice and human Alzheimer’s disease. Proceedings of the National Academy of Sciences. 10.1073/pnas.1710329115 - DOI - PMC - PubMed
-
- de Almodovar CR, Lambrechts D, Mazzone M, & Carmeliet P (2009). Role and therapeutic potential of VEGF in the nervous system. Physiological Reviews, 89(2), 607–648. - PubMed
-
- Garcia KO, Ornellas FLM, Martin PKM, Patti CL, Mello LE, Frussa-Filho R, Han SW, & Longo BM (2014). Therapeutic effects of the transplantation of VEGF overexpressing bone marrow mesenchymal stem cells in the hippocampus of murine model of Alzheimer’s disease. Frontiers in Aging Neuroscience, 6, 6–30. - PMC - PubMed
Publication types
MeSH terms
Substances
Grants and funding
- P20 AG068082/AG/NIA NIH HHS/United States
- R01 AG078803/AG/NIA NIH HHS/United States
- R01 AG064950/AG/NIA NIH HHS/United States
- R01 AG061518/AG/NIA NIH HHS/United States
- R01 HL111516/HL/NHLBI NIH HHS/United States
- R01 AG062826/AG/NIA NIH HHS/United States
- R21 AG059941/AG/NIA NIH HHS/United States
- R01 AG059716/AG/NIA NIH HHS/United States
- S10 OD023680/OD/NIH HHS/United States
- K01 AG049164/AG/NIA NIH HHS/United States
- K24 AG046373/AG/NIA NIH HHS/United States
- R01 NS100980/NS/NINDS NIH HHS/United States
- R01 AG034962/AG/NIA NIH HHS/United States
- UL1 TR001445/TR/NCATS NIH HHS/United States
- UL1 TR000445/TR/NCATS NIH HHS/United States
- RF1 AG015819/AG/NIA NIH HHS/United States
- R01 AG056534/AG/NIA NIH HHS/United States
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous